Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
2022 | Sanofi profit gain beats market view on bestseller drug Dupixent | RE |
2022 | Sanofi to float drug ingredients manufacturing business on May 6 | RE |
Financials (USD)
Sales 2008 | 22.12K | Sales 2009 | 5.22K | Capitalization | 563K |
---|---|---|---|---|---|
Net income 2008 | - | Net income 2009 | - | EV / Sales 2008 | 33.3 x |
Net Debt 2008 | 399K | Net Debt 2009 | 673K | EV / Sales 2009 | 237 x |
P/E ratio 2008 |
-0.98
x | P/E ratio 2009 |
-1.34
x | Employees | 2 |
Yield 2008 * |
-
| Yield 2009 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Ronald S. Tucker
CEO | Chief Executive Officer | 84 | 97-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ronald S. Tucker
CEO | Chief Executive Officer | 84 | 97-09-30 |
1st Jan change | Capi. | |
---|---|---|
-.--% | 20 | |
+11.28% | 6.42B | |
-33.39% | 685M | |
-36.36% | 611M | |
+84.95% | 476M | |
+182.80% | 372M | |
-57.59% | 303M | |
-13.56% | 121M | |
-.--% | 118M | |
-12.89% | 101M |
- Stock Market
- Equities
- EPOR Stock